

Press Release

ProStrakan Group plc
31 March 2010

ProStrakan Group plc Share Plans

ProStrakan Group plc (“the Company”) announces that on 26 March 2010 it made a grant of awards and options over the Company’s ordinary shares of 5 pence each under the Performance Share Plan (“PSP”) to Executive Directors and Persons Discharging Managerial Responsibilities (“PDMR”) as detailed in the table below.

| Name | Role | No of shares subject to awards | Total No. of options and awards now held |
|----------------|--------------------|--------------------------------|--|
| Wilson Totten | Executive Director | 340,000 | 4,930,964 |
| Allan Watson | Executive Director | 185,000 | 948,027 |
| Nigel Atherton | PDMR | 162,000 | 1,086,170 |
| Andrew McLean | PDMR | 156,000 | 1,436,976 |
| Abid Karim | PDMR | 200,000 | 1,413,193 |
| Tom Stratford | PDMR | 155,000 | 1,274,393 |
| Beth Tope | PDMR | 92,000 | 405,762 |

Awards granted under the PSP will vest on 26 March 2013 but only to the extent that certain performance criteria are satisfied by the Company over a three year performance period that commenced on 26 March 2010. No consideration is payable for the grant of the Awards and the receipt of ordinary 5p shares is conditional upon meeting the performance criteria. It is currently intended that the Company’s Employee Benefit Trust will acquire new shares to fulfill any obligation arising from the vesting of the Awards by 26 March 2013.

The notification of these Awards is intended to satisfy the Company's obligations under Disclosure and Transparency Rule 3.1.4.

Andrew McLean
Company Secretary

Further enquiries:

Callum Spreng 01896 664000
Corporate Communications
ProStrakan

Jon Coles/Justine McIlroy 020 7404 5959
Brunswick Group

About ProStrakan:

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels, UK, and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

www.prostrakan.com